Intellectual Property in Personalised Medicine

Jamie R Love and Edward D Blair

The economic value of intellectual property associated with prognostic and predictive tests is being increasingly recognised, such that some tests with established impact on healthcare pathways can command a premium reimbursement price from payers. Here we examine a number of seminal cases where the economic value of key tests has been hugely affected by the rulings and counter-rulings of the American justice system, with further impact on European and other markets.